Microsatellite instability and colorectal cancer

Archives of Pathology and Laboratory Medicine

Volumn 135, Issue 10, 2011, Pages 1269-1277

  Geiersbach, Katherine B ^a   Samowitz, Wade S ^a  

^a ARUP LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; MLH1 PROTEIN, HUMAN; NUCLEAR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ALGORITHM; COLORECTAL TUMOR; DNA METHYLATION; GENETIC SCREENING; GENETICS; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MUTATION; PATHOLOGY; REVIEW;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ALGORITHMS; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA METHYLATION; DNA MISMATCH REPAIR; GENETIC TESTING; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 80055083189     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2011-0035-RA     Document Type: Review

References (77)

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759-767.
2. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genetics. 1999;36(11):801-818. (Pubitemid 29520569)
3. Aaltonen L, Johns L, Järvinen H, Mecklin J-P, Houlston R. Explaining the familial colorectal cancer risk associated with mismatch repair (MMR)-deficient and MMR-stable tumors. Clin Cancer Res. 2007;13(1):356-361. (Pubitemid 46121890)
4. Warthin AS. Heredity with reference to carcinoma as shown by the study of the cases examined in the pathological laboratory of the University of Michigan, 1895-1913. Arch Intern Med. 1913;35(6):348-359.
5. Lynch HT, Shaw MW, Magnuson CW, Larsen AL, Krush AJ. Hereditary factors in cancer: study of two large midwestern kindreds. Arch Intern Med. 1966; 117(2):206-212.
6. Boland CR. Evolution of the nomenclature for the hereditary colorectal cancer syndromes. Fam Cancer. 2005;4(3):211-218. (Pubitemid 41242189)
7. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet. 2009;76(1):1-18.
8. Kastrinos F, Mukherjee B, Tayob N, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009;302(16):1790-1795.
9. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Croup on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum. 1991;34(5):424-425.
10. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999; 116(6):1453-1456. (Pubitemid 29258894)
11. Lindor NM, Rabe K, Petersen GM, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA. 2005;293(16):1979-1985. (Pubitemid 40570891)
12. Jenkins MA, Hayashi S, O'Shea AM, et al. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology. 2007;133(1):48-56. (Pubitemid 47039240)
13. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A National Cancer Institute Workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst. 1997;89(23): 1758-1762.
14. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261-268. (Pubitemid 38256271)
15. Gologan A, Krasinskas A, Hunt J, Thull DL, Farkas L, Sepulveda AR. Performance of the revised Bethesda guidelines for identification of colorectal carcinomas with a high level of microsatellite instability. Arch Pathol Lab Med. 2005;129(11):1390-1397. (Pubitemid 41587011)
16. Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 1998;338(21):1481-1487. (Pubitemid 28226275)
17. Pinol V, Castells A, Andreu M, et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA. 2005; 293(16):1986-1994. (Pubitemid 40570892)
18. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clinical Oncol. 2008,26(35): 5783-5788.
19. Hampel H. Point: justification for Lynch syndrome screening among all patients with newly diagnosed colorectal cancer. J Natl Compr Cane Netw. 2010; 8(5):597-601.
20. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352(18):1851- 1860.
21. Dinjens WN, van Leerdam ME, Wagner A. On the advent of MSI testing of all colorectal cancers and a substantial part of other Lynch syndrome-related neoplasms. Expert Rev Mol Diagn. 2010;10(4):381-384.
22. Peltomaki P, Aaltonen LA, Sistonen P, et al. Genetic mapping of a locus predisposing to human colorectal cancer. Science. 1993;260(5109):810-812. (Pubitemid 23167610)
23. Lindblom A, Tannergard P, Werelius B, Nordenskjold M. Genetic mapping of a second locus predisposing to hereditary non-polyposis colon cancer. Nat Genet. 1993;5(3):279-282. (Pubitemid 23330393)
24. Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell. 1993; 75(5):1027-1038. (Pubitemid 24014559)
25. Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell. 1993;75(6):1215- 1225. (Pubitemid 24006117)
26. Bronner CE, Baker SM, Morrison PT, et al. Mutation in the DNA mismatch repair gene homologue hMLHI is associated with hereditary non-polyposis colon cancer. Nature. 1994;368(6468):258-261.
27. Ligtenberg MJ, Kuiper RP, Chan TL, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet. 2009;41(1):112-117.
28. Kovacs ME, Papp J, Szentirmay Z, Otto S, Olah E. Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome. Hum Mutat. 2009;30(2):197-203.
29. Hendriks YM, Wagner A, Morreau H, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology. 2004;127(1):17-25. (Pubitemid 38962270)
30. Nicolaides NC, Papadopoulos N, Liu B, et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature. 1994;371(6492): 75-80. (Pubitemid 24277467)
31. Hienonen T, Laiho P, Salovaara R, et al. Little evidence for involvement of MLH3 in colorectal cancer predisposition. Int J Cancer. 2003;106(2):292-296. (Pubitemid 36835186)
32. Wu Y, Berends MJ, Sijmons RH, et al. A role for MLH3 in hereditary nonpolyposis colorectal cancer. Nat Genet. 2001;29(2):137-138. (Pubitemid 32952647)
33. Wijnen J, de Leeuw W, Vasen H, et al. Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet. 1999;23(2):142-144. (Pubitemid 29455383)
34. Berends MJ, Wu Y, Sijmons RH, et al. Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet. 2002;70(1):26-37. (Pubitemid 34031695)
35. Senter L, Clendenning M, Sotamaa K, et al. The clinical phenotype of lynch syndrome due to germ-line PMS2 mutations. Gastroenterology. 2008; 135(2):419-e428.e411.
36. Ricciardone MD, Ozcelik T, Cevher B, et al. Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1. Cancer Res. 1999;59(2):290-293. (Pubitemid 29048854)
37. Gallinger S, Aronson M, Shayan K, et al. Gastrointestinal cancers and neurofibromatosis type 1 features in children with a germline homozygous MLH1 mutation. Gastroenterology. 2004;126(2):576-585. (Pubitemid 38182314)
38. Bandipalliam P. Syndrome of early onset colon cancers, hematologic malignancies & features of neurofibromatosis in HNPCC families with homozygous mismatch repair gene mutations. Fam Cancer. 2005;4(4):323-333. (Pubitemid 41795810)
39. Felton KE, Gilchrist DM, Andrew SE. Constitutive deficiency in DNA mismatch repair: is it time for Lynch III? Clin Genet. 2007;71(6):499-500. (Pubitemid 46831943)
40. Wimmer K, Etzler J. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet. 2008;124(2):105-122.
41. Lahue RS, Au KG, Modrich P. DNA mismatch correction in a defined system. Science. 1989;245(4914):160-164. (Pubitemid 19193931)
42. Cooper DL, Lahue RS, Modrich P. Methyl-directed mismatch repair is bidirectional. ; Biol Chem. 1993;268(16):11823-11829. (Pubitemid 23168137)
43. Burdett V, Baitinger C, Viswanathan M, Lovett ST, Modrich P. In vivo requirement for RecJ, ExoVII, Exol, and ExoX in methyl-directed mismatch repair. Proc Natl Acad Sci USA. 2001;98(12):6765-6770. (Pubitemid 32538291)
44. Viswanathan M, Burdett V, Baitinger C, Modrich P, Lovett ST. Redundant exonuclease involvement in Escherichia coli methyl-directed mismatch repair. J Biol Chem. 2001;276(33):31053-31058.
45. Pluciennik A, Modrich P. Protein roadblocks and helix discontinuities are barriers to the initiation of mismatch repair. Proc Natl Acad Sci USA. 2007; 104(31):12709-12713. (Pubitemid 47255219)
46. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med. 2009;11(1):35-41.
47. Hitchins MP, Wong JJ, Suthers G, et al. Inheritance of a cancer-associated MLH1 germ-line epimutation. N Engl J Med. 2007;356(7):697-705.
48. Peltomaki P. Lynch syndrome genes. Fam Cancer. 2005;4(3):227-232. (Pubitemid 41242191)
49. Boland CR, Shike M. Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer. Gastroenterology. 2010; 138(7):2197e2191-2197.
50. Stoffel EM, Syngal S. Adenomas in young patients: what is the optimal evaluation? Am J Gastroenterol. 2005;100(5):1150-1153. (Pubitemid 40769055)
51. Cunningham JM, Christensen ER, Tester DJ, et al. Hypermethylation of the hMLHI promoter in colon cancer with microsatellite instability. Cancer Res. 1998;58(15):3455-3460. (Pubitemid 28371090)
52. Samowitz WS, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology. 2005;129(3):837-845. (Pubitemid 41242676)
53. Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLHI, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res. 2004,10(1, pt 1 ):191-195. (Pubitemid 38114179)
54. Domingo E, Laiho P, Ollikainen M, et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet. 2004; 41(9):664-668. (Pubitemid 39208606)
55. Loughrey MB, Waring PM, Tan A, et al. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary nonpolyposis colorectal cancer. Fam Cancer. 2007;6(3):301-310. (Pubitemid 47175009)
56. McGivern A, Wynter CV, Whitehall VL, et al. Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer. 2004;3(2):101-107. (Pubitemid 40645891)
57. Vaughn CP, Wilson AR, Samowitz WS. Quantitative evaluation of CpG island methylation in hyperplastic polyps. Mod Pathol. 2010;23(1):151-156.
58. Torlakovic E, Skovlund E, Snover DC, Torlakovic G, Nesland JM. Morphologic reappraisal of serrated colorectal polyps. Am J Surg Pathol. 2003,27(1 ):65-81. (Pubitemid 36014900)
59. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-B receptor in colon cancer cells with microsatellite instability. Science. 1995; 268(5215):1336-1338.
60. Rampino N, Yamamoto H, lonov Y, et al. Somatic frameshift mutations in the BAXgene in colon cancers of the microsatellite mutator phenotype. Science. 1997;275(5302):967-969. (Pubitemid 27087710)
61. Samowitz WS, Holden JA, Curtin K, et al. Inverse relationship between microsatellite instability and K-ras and p53 gene alterations in colon cancer. Am J Pathol. 2001;158(4):1517-1524. (Pubitemid 32281315)
62. Samowitz WS, Curtin K, Ma KN, et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev. 2001;10(9):917-923. (Pubitemid 32844897)
63. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349(3):247-257. (Pubitemid 36859476)
64. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24(33):5313-5327. (Pubitemid 46631379)
65. Chubak B, Heald B, Sharp RR. Informed consent to microsatellite instability and immunohistochemistry screening for Lynch syndrome. Genet Med. 2011;13(4):356-360.
66. NCCN Colon Cancer Panel Members. Colorectal Cancer Screening. Fort Washington, PA: National Comprehensive Care Network Inc; 2010. NCCN Clinical Practice Guidelines in Oncology, version 2.2011.
67. Shia J, Tang LH, Vakiani E, et al. Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol. 2009;33(11):1639-1645.
68. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome, part I: the utility of immunohistochemistry. J Mol Diagn. 2008; 10(4):293-300. (Pubitemid 352019113)
69. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58(22):5248-5257. (Pubitemid 28521189)
70. Suraweera N, Duval A, Reperant M, et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology. 2002;123(6):1804-1811. (Pubitemid 35408304)
71. Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Ruschoff J. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res. 1997;57(21):4749-4756. (Pubitemid 27468981)
72. Murphy KM, Zhang S, Geiger T, et al. Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers. J Mol Diagn. 2006;8(3):305-311. (Pubitemid 44063806)
73. Pyatt R, Chadwick RB, Johnson CK, Adebamowo C, de la Chapelle A, Prior TW. Polymorphic variation at the BAT-25 and BAT-26 loci in individuals of African origin. Implications for microsatellite instability testing. Am J Pathol. 1999;155(2):349-353. (Pubitemid 29370385)
74. Samowitz WS, Slattery ML, Potter JD, Leppert MF. BAT-26 and BAT-40 instability in colorectal adenomas and carcinomas and germline polymorphisms. Am J Pathol. 1999;154(6):1637-1641. (Pubitemid 29262844)
75. Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome, part II: the utility of microsatellite instability testing. J Mol Diagn. 2008; 10(4):301-307. (Pubitemid 352019114)
76. Capel E, Flejou JF, Hamelin R. Assessment of MLH1 promoter methylation in relation to gene expression requires specific analysis. Oncogene. 2007;26(54): 7596-7600. (Pubitemid 350207716)
77. Dinh TA, Rosner BI, Atwood JC, et al. Health benefits and costeffectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res. 2011;4(1):9-22.